Humira vs Skyrizi vs Stelara vs Cosentyx: Psoriasis Biologics Cost Comparison for 2026

Humira, Skyrizi, Stelara, and Cosentyx are FDA-approved biologic drugs for moderate to severe plaque psoriasis, and three of them also treat psoriatic arthritis. Each blocks a different inflammatory pathway: Humira (adalimumab) blocks tumor necrosis factor (TNF), Skyrizi (risankizumab-rzaa) and Stelara (ustekinumab) block interleukin-23 and interleukin-12/23 respectively, and Cosentyx (secukinumab) blocks interleukin-17A. That mechanism difference does not change how each drug is billed, but the four drugs have sharply different biosimilar status, IRA negotiation status, and manufacturer assistance programs in 2026, which is why comparing them side by side matters more for your wallet than the underlying pathway does. For single-drug detail, see the dedicated pages for Humira cost, Skyrizi cost, and Stelara cost.

The Inflation Reduction Act of 2022, signed August 16, 2022, authorized CMS to negotiate Medicare drug prices directly with manufacturers for the first time. Stelara was one of the first 10 drugs selected for Round 1 negotiation, and its Maximum Fair Price of $4,695 per 30-day supply took effect January 1, 2026. Humira already faces biosimilar competition that predates the IRA program: patents expired in 2023, and more than 10 FDA-approved biosimilars now compete on price, several priced 85 to 92 percent below Humira's brand list. Skyrizi and Cosentyx remain fully patent-protected with no biosimilar and no IRA negotiation, so their 2026 costs are set entirely by AbbVie and Novartis list pricing and each drug's manufacturer savings programs.

Patients switching between these four biologics for cost reasons should talk to their dermatologist or rheumatologist first. Dosing schedules differ substantially: Humira is typically injected every other week, Cosentyx monthly, and Skyrizi and Stelara every 12 weeks after an initial loading period. Many commercial and Medicaid formularies now require step therapy, meaning you must try and fail a lower-cost biologic (often biosimilar adalimumab) before the plan approves a costlier one like Skyrizi or Cosentyx. The comparison table below lays out cash price, Medicare treatment, biosimilar availability, and manufacturer patient assistance program for all four drugs side by side.

What Psoriasis Biologics Comparison Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same psoriasis biologics comparison can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Skyrizi and Stelara both require an intravenous induction dose for Crohn's disease and ulcerative colitis, administered in a hospital or infusion center under the buy-and-bill model. The facility purchases the drug, administers it, and bills Medicare Part B at ASP plus 6 percent, or bills a commercial payer at a separately negotiated facility rate. Commercial facility rates for the same IV dose can run several times the Medicare ASP because the chargemaster bundles drug acquisition cost with nursing time, IV supplies, infusion monitoring, and overhead allocations that have nothing to do with the drug itself.

Humira and Cosentyx are almost always self-administered by subcutaneous injection at home, so they rarely appear as inpatient hospital line items for plaque psoriasis. When either drug does appear on a hospital bill, usually because a patient was admitted for an unrelated reason and brought their own injection or the hospital dispensed a partial supply, the charge can run several times the outpatient retail rate because hospitals apply the same facility-rate markup logic used for infused drugs.

Medicare Part A stops paying for any of these four biologics the moment a patient is discharged, and coverage shifts to Part B for provider-administered IV doses or Part D for the outpatient self-injected prescription. That transition is where Stelara's 2026 IRA Maximum Fair Price of $4,695 per 30-day supply kicks in, along with standard Part D formulary-tier cost-sharing for Humira, Skyrizi, and Cosentyx. Patients discharged on a new biologic prescription without an active Part D plan or a manufacturer savings card active often face sticker shock at the outpatient specialty pharmacy because they assumed the inpatient rate would carry over.

HCPCS J-Codes: What Appears on Your Bill

Provider-administered doses of these four biologics are billed under HCPCS Level II J-codes. Most psoriasis patients self-inject at home under Part D and never see these codes, but they appear on bills for IV induction doses (Crohn's disease, ulcerative colitis) or clinic-administered injections. These codes are public domain and appear on your Explanation of Benefits (EOB) or itemized bill:

Patient Assistance Programs

AbbVie, Johnson & Johnson, and Novartis each run separate patient assistance programs for their psoriasis biologic, and the income thresholds and program mechanics differ across all four drugs. If you have no insurance and a modest income, your prescribed biologic may cost $0 through the correct manufacturer program, but you must apply to the specific manufacturer of your drug; there is no single combined psoriasis-biologic assistance program.

Medicare Part D

Medicare Part D treats these four psoriasis biologics very differently in 2026. Stelara is subject to the IRA Maximum Fair Price of $4,695 per 30-day supply, applied at any network pharmacy regardless of which specific plan you carry. Humira, Skyrizi, and Cosentyx have no negotiated price; your out-of-pocket cost depends entirely on your Part D plan's formulary tier, and most plans place adalimumab biosimilars on a much lower tier with a smaller copay than brand Skyrizi or Cosentyx. All out-of-pocket spending on any of the four drugs counts toward the same 2026 Part D annual out-of-pocket cap of $2,100; once you hit that cap across all your Part D drugs combined, you pay $0 for the rest of the calendar year.

Extra Help (the Part D Low Income Subsidy) reduces cost-sharing further for Medicare beneficiaries with limited income and resources. In 2026, Extra Help enrollees pay $12.65 per fill for a brand-name biologic like Skyrizi or Cosentyx, and a smaller copay for a biosimilar such as adalimumab-adbm or Wezlana. Extra Help is generally available to beneficiaries with income at or below 150% of the Federal Poverty Level. Apply through the Social Security Administration at 1-800-772-1213 or at ssa.gov, and mention which specific biologic you take since eligibility rules for the manufacturer PAP on top of Extra Help vary by drug.

Common Psoriasis Biologics Comparison Billing Errors

These four biologics span both Part B (IV/infusion for Skyrizi and Stelara) and Part D (subcutaneous self-injection for all four), so billing errors often involve the wrong benefit or the wrong J-code. Watch for these issues on your Explanation of Benefits or itemized bill:

• Wrong J-code: J3357 (Stelara subcutaneous) used for an IV infusion, or J3358 (Stelara IV) used for a self-administered subcutaneous dose. The same mix-up can occur between J2327 (Skyrizi IV) and a subcutaneous Skyrizi maintenance dose billed under Part D pharmacy benefits instead.
• Pharmacy charges more than the $4,695 Stelara IRA Maximum Fair Price for a Medicare Part D fill in 2026, which violates federal law; ask your plan's member services to reprocess the claim.
• Biosimilar substituted but billed as brand: your EOB shows Humira or Stelara brand charges but the pharmacy dispensed a biosimilar like Cyltezo, Hyrimoz, or Wezlana. The biosimilar should be billed at its own ASP or list rate, which differs from the brand rate.
• Manufacturer savings card applied for a patient who has Medicare or Medicaid, which is prohibited and can result in a claim clawback later.
• Step therapy denial requiring a trial of biosimilar adalimumab or another lower-cost biologic first, without documenting that the required first-step drug was already tried and failed or is clinically inappropriate.
• Charged the standard copay after you already hit the $2,100 Part D annual out-of-pocket cap for the year across all your combined Part D drugs.

Frequently Asked Questions